These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15206060)

  • 1. The pharmacogenetics of antiretroviral therapy: a review of studies to date.
    Quirk E; McLeod H; Powderly W
    Clin Infect Dis; 2004 Jul; 39(1):98-106. PubMed ID: 15206060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical implications of antiretroviral pharmacogenomics.
    Fox J; Boffito M; Winston A
    Pharmacogenomics; 2006 Jun; 7(4):587-96. PubMed ID: 16753006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 4. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics and the potential for the individualization of antiretroviral therapy.
    Phillips EJ; Mallal SA
    Curr Opin Infect Dis; 2008 Feb; 21(1):16-24. PubMed ID: 18192781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of antiretrovirals.
    Tozzi V
    Antiviral Res; 2010 Jan; 85(1):190-200. PubMed ID: 19744523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis.
    Hu K; Xiang Q; Wang Z; Mu GY; Zhang Z; Ma LY; Xie QF; Chen SQ; Zhou S; Zhang XD; Cui YM
    BMC Infect Dis; 2019 Jul; 19(1):583. PubMed ID: 31277607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
    Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
    J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.
    Hughes S; Hughes A; Brothers C; Spreen W; Thorborn D;
    Pharm Stat; 2008; 7(2):121-9. PubMed ID: 17534855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.
    Cressey TR; Lallemant M
    Infect Genet Evol; 2007 Mar; 7(2):333-42. PubMed ID: 17045554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
    Michaud V; Bar-Magen T; Turgeon J; Flockhart D; Desta Z; Wainberg MA
    Pharmacol Rev; 2012 Jul; 64(3):803-33. PubMed ID: 22759796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.
    Vidal F; Domingo P; Viladés C; Peraire J; Arnedo M; Alcamí J; Leal M; Villarroya F; Gatell JM
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1365-82. PubMed ID: 21999362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypersensitivity syndrome--the role of pharmacogenetics for prediction of efficacy and safety of antiretroviral therapy in patients with HIV/AIDS].
    Cholewińska G
    Przegl Epidemiol; 2008; 62(1):149-54. PubMed ID: 18536238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scientists find some genes a bad omen for anti-HIV drug.
    Stephenson J
    JAMA; 2002 Apr; 287(13):1637. PubMed ID: 11926874
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
    Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
    Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of adverse effects due to antiretroviral drugs.
    Vidal F; Gutiérrez F; Gutiérrez M; Olona M; Sánchez V; Mateo G; Peraire J; Viladés C; Veloso S; López-Dupla M; Domingo P
    AIDS Rev; 2010; 12(1):15-30. PubMed ID: 20216907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?
    Nolan D; Gaudieri S; Mallal S
    J HIV Ther; 2003 May; 8(2):36-41. PubMed ID: 12838163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
    King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
    J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.